Boston Trust Walden Corp Has $126.80 Million Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Boston Trust Walden Corp grew its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 10.0% in the fourth quarter, HoldingsChannel reports. The fund owned 1,379,290 shares of the medical device company’s stock after acquiring an additional 125,475 shares during the period. Cooper Companies makes up 0.9% of Boston Trust Walden Corp’s portfolio, making the stock its 21st largest position. Boston Trust Walden Corp’s holdings in Cooper Companies were worth $126,798,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Ashton Thomas Securities LLC acquired a new position in Cooper Companies during the third quarter valued at approximately $25,000. Covestor Ltd boosted its holdings in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after buying an additional 200 shares during the last quarter. Brown Brothers Harriman & Co. grew its stake in shares of Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after buying an additional 275 shares in the last quarter. Friedenthal Financial bought a new position in shares of Cooper Companies in the third quarter valued at $50,000. Finally, Cromwell Holdings LLC acquired a new position in Cooper Companies during the third quarter worth $52,000. 24.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on COO shares. StockNews.com cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Citigroup lowered their price target on Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, December 6th. Wells Fargo & Company raised their price objective on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Friday, December 6th. Finally, Morgan Stanley decreased their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Stock Down 1.6 %

COO stock opened at $96.55 on Monday. The Cooper Companies, Inc. has a fifty-two week low of $84.76 and a fifty-two week high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The stock has a market capitalization of $19.27 billion, a price-to-earnings ratio of 49.51, a PEG ratio of 2.45 and a beta of 1.00. The business’s fifty day moving average price is $95.79 and its two-hundred day moving average price is $99.71.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Cooper Companies’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same period last year, the firm earned $0.87 earnings per share. On average, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.